Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHELLE D WELCH

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1891764957
CMS profile
358563
Location
SHAVANO PARK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$29,400.35

257 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 6; records 51–100 of 257 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHELLE D WELCH

NPI 1891764957 · CMS profile ID 358563

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

SHAVANO PARK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 257 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891764957?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHELLE D WELCH, NPI 1891764957, CMS profile ID 358563. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 257 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891764957?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MICHELLE D WELCH, NPI 1891764957, CMS profile ID 358563. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 257 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891764957?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MICHELLE D WELCH, NPI 1891764957, CMS profile ID 358563, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 257 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1891764957?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

257 matching records · $29,400.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 257 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 257.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $950.0010/27/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736057691 CMS
Novo Nordisk Inc $8.6310/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744976077 CMS
Antares Pharma, Inc. $15.4110/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751426171 CMS
AstraZeneca Pharmaceuticals LP $950.0010/22/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736210769 CMS
Lilly USA, LLC $18.4010/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728574261 CMS
AstraZeneca Pharmaceuticals LP $22.1610/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736033885 CMS
AstraZeneca Pharmaceuticals LP $16.6610/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736101895 CMS
Lilly USA, LLC $14.8710/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728557557 CMS
AbbVie Inc. $22.9210/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722178933 CMS
SANOFI-AVENTIS U.S. LLC $9.0910/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744171729 CMS
Strongbridge US INC. $13.5410/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735173655 CMS
Lilly USA, LLC $650.0010/13/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728551053 CMS
Novo Nordisk Inc $1.3710/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744965781 CMS
Novo Nordisk Inc $13.3410/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744965791 CMS
AstraZeneca Pharmaceuticals LP $950.0010/12/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736123755 CMS
Corcept Therapeutics $16.2810/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744750349 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.5810/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720591843 CMS
Lilly USA, LLC $650.0010/08/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728564335 CMS
Novo Nordisk Inc $20.0610/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744896335 CMS
AstraZeneca Pharmaceuticals LP $950.0010/06/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736318033 CMS
Zealand Pharma US, Inc. $19.5410/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739669813 CMS
Antares Pharma, Inc. $17.3810/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751426159 CMS
AstraZeneca Pharmaceuticals LP $950.0009/28/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736302599 CMS
AbbVie Inc. $19.8109/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722178931 CMS
Novo Nordisk Inc $20.8409/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744992721 CMS
AstraZeneca Pharmaceuticals LP $110.5509/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736225865 CMS
Insulet Corporation $35.5809/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748421131 CMS
Lilly USA, LLC $650.0009/17/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728574265 CMS
AstraZeneca Pharmaceuticals LP $11.2709/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735974729 CMS
Mannkind Corporation $18.1809/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752690022 CMS
Novo Nordisk Inc $2.1209/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744911193 CMS
Novo Nordisk Inc $14.5709/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744911203 CMS
IBSA Pharma Inc. $17.9809/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719686013 CMS
AstraZeneca Pharmaceuticals LP $19.5709/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736130261 CMS
Abbott Laboratories $19.7909/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749024179 CMS
Amgen Inc. $14.9409/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741234251 CMS
Mannkind Corporation $20.3209/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752690018 CMS
Antares Pharma, Inc. $16.3809/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751426165 CMS
AstraZeneca Pharmaceuticals LP $13.1808/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736395251 CMS
Insulet Corporation $33.1708/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748421153 CMS
Lilly USA, LLC $14.3508/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728554123 CMS
AbbVie Inc. $25.9108/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722178929 CMS
Novo Nordisk Inc $18.8508/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744867967 CMS
Amarin Pharma Inc. $20.1608/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740080003 CMS
Merck Sharp & Dohme Corporation $12.1608/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747773781 CMS
AstraZeneca Pharmaceuticals LP $14.9708/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736390021 CMS
AstraZeneca Pharmaceuticals LP $950.0008/23/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735865179 CMS
Insulet Corporation $36.2908/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748421151 CMS
AstraZeneca Pharmaceuticals LP $16.9708/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736410623 CMS
AstraZeneca Pharmaceuticals LP $14.7008/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736178767 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $118,148.48 418
PY2020 $29,400.35 257
PY2021 $33,854.00 215
PY2022 $83,212.53 263
PY2023 $64,209.18 190
PY2024 $85,284.18 228
PY2025 $42,488.67 174

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,768,634.20 449
PY2024 Recipient $105,211.00 8
PY2024 Principal investigator $2,664,060.78 826
PY2023 Recipient $7,665.94 7
PY2023 Principal investigator $2,566,952.03 465
PY2022 Recipient $76,525.00 9
PY2022 Principal investigator $1,989,989.08 364
PY2021 Recipient $7,260.42 3
PY2021 Principal investigator $2,662,897.61 571
PY2020 Recipient $17,198.80 12
PY2020 Principal investigator $1,760,442.61 143
PY2019 Recipient $8,139.00 2
PY2019 Principal investigator $1,428,906.85 208

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

449 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202533825
Principal investigator 1 Eli Lilly and Company $8,268.00 12/30/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES (SYNERGY-OUTCOMES); N1T-MC-TZ01; N1T-MC-RT01 No dispute reported 06/30/2026 1187880255
Principal investigator 1 PFIZER INC. $1,227.94 12/24/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 1228746733
Principal investigator 1 Eli Lilly and Company $4,792.00 12/23/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 2, RANDOMIZED, OPEN-LABEL, COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3938577 IN STUDY PARTICIPANTS, WITH TYPE 2 DIABETES MELLITUS PREVIOUSLY TREATED WITH BASAL INSULIN No dispute reported 06/30/2026 1187881414
Principal investigator 1 Novo Nordisk AS $209.82 12/22/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN8640-4515 No dispute reported 06/30/2026 1213703437
Principal investigator 1 Novo Nordisk AS $1,540.13 12/22/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4352 No dispute reported 06/30/2026 1213729689
Principal investigator 1 Novo Nordisk AS $1,104.19 12/22/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4352 No dispute reported 06/30/2026 1213758565
Principal investigator 1 Genentech, Inc. $4,889.00 12/19/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211590585
Principal investigator 1 Genentech, Inc. $2,561.00 12/19/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590589
Principal investigator 1 Hoffmann-La Roche Limited $3,152.00 12/19/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211590630
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 12/18/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220995144
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 12/17/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647301
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 12/17/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647303
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 12/17/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647305
Principal investigator 1 Boehringer Ingelheim International GmbH $12.42 12/17/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647307
Principal investigator 1 Eli Lilly and Company $915.38 12/17/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187878743
Principal investigator 1 Eli Lilly and Company $1,395.66 12/17/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187880047
Principal investigator 1 Eli Lilly and Company $28,189.00 12/15/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT REDUCTION WITH MACUPATIDE AND ELORALINTIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187881412
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,386.60 12/10/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220819025
Principal investigator 1 ABBVIE INC. $2,306.56 12/05/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529258
Principal investigator 1 Genentech, Inc. $1,500.00 12/04/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590561
Principal investigator 1 Genentech, Inc. $10,964.00 12/04/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590565
Principal investigator 1 Genentech, Inc. $1,492.00 12/04/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590569
Principal investigator 1 Genentech, Inc. $1,000.00 12/04/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590572
Principal investigator 1 Genentech, Inc. $8,500.00 12/04/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590576
Principal investigator 1 Genentech, Inc. $205.00 12/04/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590580
Principal investigator 1 Genentech, Inc. $3,000.00 12/04/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590592
Principal investigator 1 Hoffmann-La Roche Limited $3,278.00 12/04/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211590634
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.55 12/04/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269199
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647289
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647291
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647293
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647295
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647297
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647299
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647479
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647481
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647483
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220647499
Principal investigator 1 Genentech, Inc. $7,676.00 11/25/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211590549
Principal investigator 1 Genentech, Inc. $3,925.00 11/20/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211590545
Principal investigator 1 Genentech, Inc. $746.00 11/20/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590557
Principal investigator 1 Hoffmann-La Roche Limited $1,233.00 11/20/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211590626
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,975.78 11/20/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263663
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 11/19/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647485
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 11/19/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647487
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 11/19/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647489
Principal investigator 1 Genentech, Inc. $2,698.00 11/14/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590541
Principal investigator 1 Hoffmann-La Roche Limited $8,616.00 11/14/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211590621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,061.93 11/14/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261327
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,862.60 11/13/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220819041
Principal investigator 1 Amgen Inc. $6,493.04 11/10/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH, LLC
A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease No dispute reported 06/30/2026 1246640507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,248.68 11/07/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258967
Principal investigator 1 PFIZER INC. $96.00 11/06/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 1228715677
Principal investigator 1 PFIZER INC. $96.00 11/06/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 1228718399
Principal investigator 1 ABBVIE INC. $59,703.04 11/05/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522503
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647275
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647277
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647279
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647281
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647283
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647285
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647287
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647475
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647477
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 11/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220647491
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 11/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220647493
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220647495
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 11/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220647497
Principal investigator 1 Genentech, Inc. $5,553.00 10/29/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211590517
Principal investigator 1 Novo Nordisk AS $823.32 10/29/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1213704113
Principal investigator 1 Novo Nordisk AS $748.69 10/29/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4352 No dispute reported 06/30/2026 1213755235
Principal investigator 1 Novo Nordisk AS $250.00 10/29/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1213756218
Principal investigator 1 Novo Nordisk AS $1,800.00 10/29/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1213756904
Principal investigator 1 Novo Nordisk AS $2,250.00 10/29/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1213845137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,267.44 10/29/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184253704
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 10/27/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220647501
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220647503
Principal investigator 1 Genentech, Inc. $746.00 10/23/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590528
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 10/16/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220793669
Principal investigator 1 Genentech, Inc. $1,206.00 10/16/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590521
Principal investigator 1 Hoffmann-La Roche Limited $6,538.00 10/16/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211590596
Principal investigator 1 Hoffmann-La Roche Limited $1,154.00 10/16/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211590600
Principal investigator 1 Hoffmann-La Roche Limited $8,456.00 10/16/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211590605
Principal investigator 1 Hoffmann-La Roche Limited $26,213.00 10/16/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211590609
Principal investigator 1 Hoffmann-La Roche Limited $1,500.00 10/16/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211590613
Principal investigator 1 Hoffmann-La Roche Limited $646.00 10/16/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211590617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,852.33 10/16/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250601
Principal investigator 1 Eli Lilly and Company $638.16 10/14/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES No dispute reported 06/30/2026 1187878075
Principal investigator 1 Genentech, Inc. $11,470.00 10/09/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211590524
Principal investigator 1 Genentech, Inc. $2,238.00 10/09/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590536
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,687.45 10/09/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184248960
Principal investigator 1 Genentech, Inc. $2,627.00 10/03/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,440.95 10/03/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,885.13 10/03/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244643
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647261
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647263
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647265
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647267
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647269
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647271
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647273
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647471
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647473
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 09/24/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647251
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 09/24/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647253
Principal investigator 1 Boehringer Ingelheim International GmbH $803.00 09/24/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647255
Principal investigator 1 Boehringer Ingelheim International GmbH $22.62 09/24/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647257
Principal investigator 1 Boehringer Ingelheim International GmbH $20.70 09/24/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647259
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 09/24/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647463
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 09/24/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647465
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 09/24/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647467
Principal investigator 1 Boehringer Ingelheim International GmbH $8.28 09/24/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647469
Principal investigator 1 Eli Lilly and Company $575.75 09/24/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187878073
Principal investigator 1 Eli Lilly and Company $304.00 09/24/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187878741
Principal investigator 1 Novo Nordisk AS $2,858.89 09/19/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN8640-4467 No dispute reported 06/30/2026 1213777013
Principal investigator 1 ABBVIE INC. $5,333.04 09/17/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202511186
Principal investigator 1 Novo Nordisk AS $1,000.00 09/17/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1213721775
Principal investigator 1 Novo Nordisk AS $500.00 09/17/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1213739013
Principal investigator 1 Novo Nordisk AS $3,000.00 09/17/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1213796789
Principal investigator 1 Genentech, Inc. $16,590.00 09/12/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211590484
Principal investigator 1 Genentech, Inc. $746.00 09/12/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590486
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/11/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220793665
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/11/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220793667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,791.48 09/10/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,474.26 09/03/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235001
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647201
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647203
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647205
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647207
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647209
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647211
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647239
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647433
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647435
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 08/26/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647457
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 08/26/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647459
Principal investigator 1 Boehringer Ingelheim International GmbH $12.42 08/26/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647461
Principal investigator 1 Genentech, Inc. $3,639.00 08/26/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,770.26 08/26/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230351
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,868.48 08/21/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220819039
Principal investigator 1 Genentech, Inc. $2,431.00 08/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211590496
Principal investigator 1 Genentech, Inc. $9,724.00 08/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211590505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,580.21 08/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184229747
Principal investigator 1 Genentech, Inc. $746.00 08/14/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,362.55 08/14/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228313
Principal investigator 1 Genentech, Inc. $36,880.00 08/07/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211590479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,695.08 08/07/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,740.41 08/07/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226141
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647237
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647429
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647431
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 07/28/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647241
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 07/28/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647243
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 07/28/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647245
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 07/28/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647247
Principal investigator 1 Boehringer Ingelheim International GmbH $20.70 07/28/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647249
Principal investigator 1 Genentech, Inc. $2,826.00 07/22/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590508
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,229.96 07/22/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217769
Principal investigator 1 Novo Nordisk AS $2,302.50 07/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1213745550
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,666.35 07/17/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217070
Principal investigator 1 Genentech, Inc. $8,035.00 07/10/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211590493
Principal investigator 1 Genentech, Inc. $746.00 07/10/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,093.99 07/10/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214366
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,744.86 07/10/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214368
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $853.20 07/09/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220819037
Principal investigator 1 ABBVIE INC. $9,437.44 07/02/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495565
Principal investigator 1 PFIZER INC. $1,150.50 07/02/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228762958
Principal investigator 1 Boehringer Ingelheim International GmbH $123.15 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647213
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647215
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647217
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647219
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647221
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647223
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647225
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647227
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647229
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647231
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647233
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647235
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647437
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647439
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647441
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647443
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647445
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647447
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647449
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647451
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647453
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647455
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,800.82 06/27/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH, LLC
A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1185552057
Principal investigator 1 PFIZER INC. $32,143.43 06/26/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228775695
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,893.40 06/25/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220819035
Principal investigator 1 Novo Nordisk AS $798.19 06/25/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4352 No dispute reported 06/30/2026 1213721760
Principal investigator 1 Novo Nordisk AS $2,818.53 06/25/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN8640-4467 No dispute reported 06/30/2026 1213820812
Principal investigator 1 Novo Nordisk AS $949.22 06/25/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4352 No dispute reported 06/30/2026 1213842965
Principal investigator 1 Eli Lilly and Company $245,007.00 06/24/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187880375
Principal investigator 1 F. Hoffmann-La Roche AG $2,111.00 06/24/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590468
Principal investigator 1 F. Hoffmann-La Roche AG $4,183.00 06/24/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $855.28 06/24/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184210644
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,494.00 06/24/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184210646
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $855.28 06/24/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184210648
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,375.00 06/12/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220819023
Principal investigator 1 F. Hoffmann-La Roche AG $8,995.00 06/05/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590459
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 06/05/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590463
Principal investigator 1 F. Hoffmann-La Roche AG $3,000.00 06/05/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211590472
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,332.70 06/05/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204179
Principal investigator 1 ABBVIE INC. $15,069.44 06/03/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202487703
Principal investigator 1 Amgen Inc. $36,153.46 06/02/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH, LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246640509
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647179
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647181
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647183
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647185
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647187
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647189
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647191
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647193
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647195
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647197
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647199
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647409
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647411
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647413
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647415
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647417
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647419
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647421
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647423
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647425
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647427
Principal investigator 1 Eli Lilly and Company $65.00 05/30/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1187890092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,271.89 05/28/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,649.93 05/22/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,033.18 05/22/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,238.71 05/22/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197597
Principal investigator 1 Eli Lilly and Company $2,539.01 05/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187878511
Principal investigator 1 Novo Nordisk AS $1,334.02 05/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN8640-4515 No dispute reported 06/30/2026 1213750985
Principal investigator 1 PFIZER INC. $4,852.58 05/14/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228764397
Principal investigator 1 Eli Lilly and Company $93,052.00 05/13/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187878505
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $70.00 05/12/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220793661
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $70.00 05/12/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220793663
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,706.40 05/09/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220819033
Principal investigator 1 ABBVIE INC. $14,690.56 05/07/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202482533
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $87.58 05/06/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220793659
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,351.40 05/05/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220819021
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647157
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647159
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647161
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647163
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647165
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647167
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647169
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647171
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647173
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647175
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647177
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647389
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647391
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647393
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647395
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647397
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647399
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647401
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647403
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647405
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647407
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,868.30 05/01/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220819031
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,575.71 04/30/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH, LLC
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185552059
Principal investigator 1 Eli Lilly and Company $527.00 04/30/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1187881410
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,848.73 04/28/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184190793
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $7,075.45 04/24/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187878507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,387.91 04/23/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189139
Principal investigator 1 Eli Lilly and Company $3,050.78 04/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL (SURMOUNT-ADOLESCENTS-2) No dispute reported 06/30/2026 1187878739
Principal investigator 1 Eli Lilly and Company $550.00 04/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS No dispute reported 06/30/2026 1187881408
Principal investigator 1 Novo Nordisk AS $1,172.54 04/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4352 No dispute reported 06/30/2026 1213707697
Principal investigator 1 Novo Nordisk AS $487.50 04/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4352 No dispute reported 06/30/2026 1213746708
Principal investigator 1 Novo Nordisk AS $150.00 04/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN8640-4467 No dispute reported 06/30/2026 1213756641
Principal investigator 1 Novo Nordisk AS $949.22 04/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4352 No dispute reported 06/30/2026 1213759202
Principal investigator 1 Novo Nordisk AS $2,750.00 04/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4352 No dispute reported 06/30/2026 1213832456
Principal investigator 1 PFIZER INC. $10,253.44 04/18/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228779755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,460.82 04/15/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183448
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,373.10 04/11/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220819019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,776.84 04/08/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184182066
Principal investigator 1 Eli Lilly and Company $41,234.00 04/07/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS ON A STABLE DOSE OF TIRZEPATIDE OR SEMAGLUTIDE WHO FAILED TO ACHIEVE HBA1C GOAL No dispute reported 06/30/2026 1187878071
Principal investigator 1 ABBVIE INC. $2,611.20 04/03/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202471588
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647135
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647137
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647139
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647141
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647143
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647145
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647147
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647149
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647151
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647153
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647155
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647369
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647371
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647373
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647375
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647377
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647379
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647381
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647383
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647385
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,999.14 04/01/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180900
Principal investigator 1 Novo Nordisk AS $372.60 03/31/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1213817745
Principal investigator 1 Eli Lilly and Company $4,300.00 03/28/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY WITH AN OPEN-LABEL EXTENSION ASSESSING THE EFFICACY, SAFETY, AND PHARMACOKINETICS PHARMACODYNAMICS OF TIRZEPATIDE IN PEDIATRIC AND ADOLESCENT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED WITH METFORMIN, OR BASAL INSULIN, OR BOTH No dispute reported 06/30/2026 1187878815
Principal investigator 1 Novo Nordisk AS $1,051.24 03/28/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN8640-4467 No dispute reported 06/30/2026 1213812790
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,770.29 03/25/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178842
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,550.00 03/25/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178844
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,855.00 03/25/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178846
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,422.00 03/25/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178848
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $611.00 03/25/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178850
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,015.10 03/24/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220819029
Principal investigator 1 PFIZER INC. $10,161.78 03/22/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228798047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,993.45 03/19/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174560
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,916.10 03/13/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220819017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,960.27 03/11/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170874
Principal investigator 1 ABBVIE INC. $12,185.60 03/07/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202460435
Principal investigator 1 PFIZER INC. $96.00 03/06/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 1228706831
Principal investigator 1 PFIZER INC. $96.00 03/06/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 1228771229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,515.11 03/04/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156736
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647099
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647101
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647103
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647105
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647107
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647109
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647111
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647113
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647115
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647117
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647119
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647349
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647351
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647353
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647355
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647357
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647359
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647361
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647363
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647365
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647367
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 02/25/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647127
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 02/25/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647129
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 02/25/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647131
Principal investigator 1 Eli Lilly and Company $274.50 02/25/2025 Non-covered Recipient Entity
COTTON ONEIL MSD OF STORMONT VAIL HEALTHCARE
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187878531
Principal investigator 1 Eli Lilly and Company $45,354.00 02/25/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187880369
Principal investigator 1 Eli Lilly and Company $2,584.00 02/25/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187890338
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,689.55 02/25/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184155406
Principal investigator 1 Novo Nordisk AS $1,837.98 02/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4352 No dispute reported 06/30/2026 1213734522
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,748.30 02/20/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220819015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,894.21 02/18/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154222
Principal investigator 1 PFIZER INC. $8,120.13 02/14/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228771168
Principal investigator 1 PFIZER INC. $169.00 02/13/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 1228771293
Principal investigator 1 Novo Nordisk AS $1,500.00 02/07/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4984 No dispute reported 06/30/2026 1213819687
Principal investigator 1 ABBVIE INC. $7,165.44 02/06/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202449265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,347.20 02/05/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152462
Principal investigator 1 Eli Lilly and Company $138,997.00 02/04/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187878509
Principal investigator 1 Eli Lilly and Company $411.75 02/03/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187880495
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647077
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647079
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647081
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647083
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647085
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647087
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647089
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647091
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647093
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647095
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647097
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647329
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647331
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647333
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647335
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647337
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647339
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647341
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647343
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647345
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647347
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,095.00 02/01/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220819013
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $465.00 01/31/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GLARGINE, WITH OR WITHOUT METFORMIN AND/?OR SGLT-2 INHIBITOR (ACHIEVE-5) No dispute reported 06/30/2026 1187878747
Principal investigator 1 Eli Lilly and Company $426.88 01/31/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187878503
Principal investigator 1 Eli Lilly and Company $626.42 01/31/2025 Non-covered Recipient Entity
COTTON ONEIL MSD OF STORMONT VAIL HEALTHCARE
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187878535
Principal investigator 1 Eli Lilly and Company $1,018.63 01/31/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) No dispute reported 06/30/2026 1187878821
Principal investigator 1 Eli Lilly and Company $1,394.16 01/31/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187880045
Principal investigator 1 Novo Nordisk AS $1,433.70 01/31/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1213706833
Principal investigator 1 Novo Nordisk AS $1,000.00 01/31/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN8640-4467 No dispute reported 06/30/2026 1213743931
Principal investigator 1 Novo Nordisk AS $3,780.00 01/31/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN8640-4467 No dispute reported 06/30/2026 1213784510
Principal investigator 1 Novo Nordisk AS $374.35 01/31/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH
NN9535-4352 No dispute reported 06/30/2026 1213830855
Principal investigator 1 AstraZeneca Pharmaceuticals LP $195,819.40 01/29/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH, LLC
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity No dispute reported 06/30/2026 1185552061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,856.51 01/29/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149890
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 01/27/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647121
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 01/27/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647123
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 01/27/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647125
Principal investigator 1 Eli Lilly and Company $1,287.98 01/27/2025 Non-covered Recipient Entity
COTTON ONEIL MSD OF STORMONT VAIL HEALTHCARE
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL (SURMOUNT-ADOLESCENTS-2) No dispute reported 06/30/2026 1187878447
Principal investigator 1 Eli Lilly and Company $4,464.18 01/27/2025 Non-covered Recipient Entity
STUDYMETRIX RESEARCH LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187893356
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,840.46 01/27/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190310939
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,638.00 01/22/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220819011
Principal investigator 1 Eli Lilly and Company $33,587.00 01/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GLARGINE, WITH OR WITHOUT METFORMIN AND/?OR SGLT-2 INHIBITOR (ACHIEVE-5) No dispute reported 06/30/2026 1187880367
Principal investigator 1 Eli Lilly and Company $25,240.00 01/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187880493
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,931.90 01/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190312463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,210.24 01/21/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149058
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,574.70 01/17/2025 Non-covered Recipient Entity
Consano Clinical Research LLC
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220819027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,690.71 01/17/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $99,076.20 01/17/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148115
Principal investigator 1 Eli Lilly and Company $8,940.63 01/13/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187880491
Principal investigator 1 Eli Lilly and Company $21,602.59 01/09/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187878391
Principal investigator 1 Eli Lilly and Company $5,645.31 01/09/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187878823
Principal investigator 1 Eli Lilly and Company $824.47 01/07/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) No dispute reported 06/30/2026 1187878813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,249.97 01/07/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145836
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,379.10 01/07/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145838
Principal investigator 1 Eli Lilly and Company $171,510.00 01/06/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1187878499
Principal investigator 1 Eli Lilly and Company $87,394.00 01/06/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) No dispute reported 06/30/2026 1187878501
Principal investigator 1 Eli Lilly and Company $378.37 01/06/2025 Non-covered Recipient Entity
COTTON ONEIL MSD OF STORMONT VAIL HEALTHCARE
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1187878767
Principal investigator 1 Eli Lilly and Company $30,645.08 01/06/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187878817
Principal investigator 1 Eli Lilly and Company $162,449.49 01/06/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL (SURMOUNT-ADOLESCENTS-2) No dispute reported 06/30/2026 1187878819
Principal investigator 1 Eli Lilly and Company $51,532.00 01/06/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187879675
Principal investigator 1 Eli Lilly and Company $279,288.00 01/06/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187879677
Principal investigator 1 Eli Lilly and Company $91,123.00 01/06/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187879679
Principal investigator 1 Eli Lilly and Company $19,101.00 01/06/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187880253
Principal investigator 1 Eli Lilly and Company $100,659.00 01/06/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187880371
Principal investigator 1 Eli Lilly and Company $61,576.00 01/06/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) No dispute reported 06/30/2026 1187880373
Principal investigator 1 Eli Lilly and Company $716,134.00 01/06/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187881406
Principal investigator 1 Eli Lilly and Company $83,573.00 01/06/2025 Non-covered Recipient Entity
CONSANO CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187882644
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647057
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647059
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647061
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647063
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647065
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647067
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647069
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647071
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647073
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647075
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220647133
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647309
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647311
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647313
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647315
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647317
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647319
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647321
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647323
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647325
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Consano Clinical Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220647327